Business

Biokin cancer drug enters national medical insurance list

By Zhang Chenxu | chinadaily.com.cn

Updated: 2026-11-17 15:39

Share - WeChat

A domestically developed cancer drug has been added to China's national medical insurance drug list in its first year on the market, its developer said.

The drug, izalontamab brengitecan, or iza-bren, was developed by Biokin Pharmaceutical, a biopharmaceutical company in Chengdu, Sichuan province.

China unveiled the 2026 list on Saturday at a conference on the high-quality development of innovative drugs in Suzhou, Jiangsu province.

The listing will make the drug reimbursable for eligible adults whose previous treatments have failed to control recurrent or metastatic nasopharyngeal cancer, a cancer of the upper throat behind the nose.

Biokin said iza-bren is the world's first and only approved bispecific antibody-drug conjugate targeting EGFR and HER3, two proteins involved in tumor growth. The therapy uses an antibody that recognizes both proteins to deliver cancer-killing medicine to tumor cells.

The drug benefited from a new pre-application mechanism that allows eligible medicines to apply for inclusion in the insurance list after completing technical review but before receiving formal marketing approval.

Zhu Yi, founder, chairman and chief scientist of Biokin, addresses a national conference on the high-quality development of innovative drugs in Suzhou, Jiangsu province, on Nov 14, 2026.[Photo provided to chinadaily.com.cn]

Zhu Yi, founder, chairman and chief scientist of Biokin, said the drug's inclusion underscored policy support for original innovation and efforts to bring medicines with breakthrough therapeutic benefits to patients more quickly.

"This gives us the confidence to step up investment and pursue innovation that can deliver breakthroughs in treatment," Zhu said at the conference in Suzhou.

Copyright 1994 -

Registration Number: 130349

Mobile